Knights Templar Eye Foundation

Knights Templar Eye Foundation The Knights Templar Eye Foundation, incorporated in 1956, is a charity sponsored by the GEKT.

The Knights Templar Eye Foundation, incorporated in 1956, is a charity sponsored by the Grand Encampment of Knights Templar. The Foundation is governed by a Board of Trustees comprised of the six elected officers of the Grand Encampment, all Past Grand Masters of the Grand Encampment, and six trustees-at-large elected from and by the membership for a term of nine years. It is exempt from federal i

ncome taxation under Section 501(c)3 of the Internal Revenue Code and contributions made to the Foundation are deductible by donors. The original mission of the Foundation was “to provide assistance to those who face loss of sight due to the need for surgical treatment without regard to race, color, creed, age, s*x or national origin provided they are unable to pay or receive adequate assistance from current government agencies or similar sources and to provide funds for research in curing diseases of the eye.”

On December 31, 2010, the Knights Templar Eye Foundation, Inc., by direction of the board, shifted the Foundation’s focus and adopted a new mission statement “to improve vision through research, education, and supporting access to care.” The Foundation now only participates in direct patient care through the Seniors Eye Care Program in partnership with EyeCare America and the Foundation of the American Academy of Ophthalmology. With this change, the Foundation is benefitting untold millions in generations to come through grants that support research and education. Our research dollars have helped develop new, nonsurgical, treatments for strabismus (crossed eyes) and ophthalmologists have told us that our efforts in funding pediatric ophthalmology research have been the primary reason that there are fewer and fewer surgeries for strabismus. The Knights Templar Eye Foundation, Inc., annually announces its call for research grant applications. The Foundation invites eligible investigators to submit applications for pediatric ophthalmology research grants for the award period which normally runs from July 1 to June 30. From the applications received, the Scientific Advisory Committee recommends to the Trustees which requests should be funded.

We believe this program is an important expansion of our support efforts. By extending a helping hand to researchers at ...
06/22/2026

We believe this program is an important expansion of our support efforts. By extending a helping hand to researchers at the beginning of their careers, we hope to encourage and accelerate advancements in vision research and ophthalmology. For many ARVO members, Travel Grants make the critical difference in being able to attend the Annual Meeting and present their research.

We believe this program is an important expansion of our support efforts. By extending a helping hand to researchers at the beginning of their careers, we hope to encourage and accelerate advancements in vision research and ophthalmology.

The Officers and Directors of the Knights Templar Eye Foundation wish to thank all Grand  Commanderies that have become ...
06/09/2026

The Officers and Directors of the Knights Templar Eye Foundation wish to thank all Grand Commanderies that have become either 100% or 200% Life Sponsors within their jurisdiction and to those Grand Commanderies that are actively working towards the 100% goal.

The Officers and Directors of the Knights Templar Eye Foundation wish to thank all Grand Commanderies that have become either 100% or 200% Life Sponsors within their jurisdiction and to those Grand Commanderies that are actively working towards the 100% goal.

On Memorial Day, we remember and honor the fallen who sacrificed for our freedom.
05/25/2026

On Memorial Day, we remember and honor the fallen who sacrificed for our freedom.

Dr. Szczepan will test this hypothesis using genetically modified mouse lines and disease models with two aims: (1) to d...
05/06/2026

Dr. Szczepan will test this hypothesis using genetically modified mouse lines and disease models with two aims: (1) to determine whether glial c-Fos controls the development of abnormal retinal neovascularization in an ROP mouse model; and (2) to determine what controls glial activation and glia mediated-retinal inflammation during retinal neovascularization. Successful completion of the proposed research will strengthen her understanding of ROP disease and lead to new therapeutic strategies.

Dr. Szczepan will test this hypothesis using genetically modified mouse lines and disease models with two aims: (1) to determine whether glial c-Fos controls the development of abnormal retinal neovascularization in an ROP mouse model; and (2) to determine what controls glial activation and glia med

Her work will improve genetic diagnosis and subsequent care and treatment for children with cataracts.
04/29/2026

Her work will improve genetic diagnosis and subsequent care and treatment for children with cataracts.

Dr. Rossen will complete gene-disease associations and variant curation guidelines for the thirteen Crystallin genes, which are associated with approximately half of all isolated pediatric cataracts, by standard methods and compare them to an accelerated Artificial Intelligence (AI)-supported workfl

In this research project, Dr. Ramshekar, focuses on the role of VEGF signaling in the development of retinal ganglion ce...
04/22/2026

In this research project, Dr. Ramshekar, focuses on the role of VEGF signaling in the development of retinal ganglion cells – a specific type of retinal neuron. He predicts that VEGF signaling is needed not only for retinal blood vessel growth but also for retinal ganglion cell development in the retina. The data from this project will better define the role of VEGF signaling in the development of retinal neurons. This research has the potential to provide new insights into how doctors can better treat and prevent vision loss in children affected by ROP.

He predicts that VEGF signaling is needed not only for retinal blood vessel growth but also for retinal ganglion cell development in the retina. The data from this project will better define the role of VEGF signaling in the development of retinal neurons. This research has the potential to provide

Happy Easter from the Knights Templar Eye Foundation!
04/05/2026

Happy Easter from the Knights Templar Eye Foundation!

Address

3201 Cross Timbers Road Bldg 4 Ste 300
Flower Mound, TX
75028

Alerts

Be the first to know and let us send you an email when Knights Templar Eye Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share